1216152-26-9 Usage
Uses
Used in Pharmaceutical Industry:
4-bromo-1-(cyclopropylmethyl)-1H-pyrazole(SALTDATA: HCl) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to the advancement of medicine and healthcare.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-1-(cyclopropylmethyl)-1H-pyrazole(SALTDATA: HCl) serves as an essential building block for the creation of novel agrochemicals. Its incorporation into these products can enhance crop protection and yield, supporting sustainable agricultural practices.
Used in Material Science:
4-bromo-1-(cyclopropylmethyl)-1H-pyrazole(SALTDATA: HCl) is utilized in material science for its potential to contribute to the development of new materials with unique properties. Its integration into material compositions can lead to innovations in various applications, including electronics, coatings, and adhesives.
Used in Organic Synthesis:
As a building block for organic synthesis, 4-bromo-1-(cyclopropylmethyl)-1H-pyrazole(SALTDATA: HCl) is employed in the creation of a wide range of organic compounds. Its versatility in chemical reactions enables the synthesis of complex molecules for various applications, from pharmaceuticals to specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1216152-26-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,6,1,5 and 2 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1216152-26:
(9*1)+(8*2)+(7*1)+(6*6)+(5*1)+(4*5)+(3*2)+(2*2)+(1*6)=109
109 % 10 = 9
So 1216152-26-9 is a valid CAS Registry Number.
1216152-26-9Relevant academic research and scientific papers
PROTEIN KINASE INHIBITORS
-
Paragraph 0142, (2015/02/18)
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
PROTEIN KINASE INHIBITORS
-
Page/Page column 33, (2013/04/25)
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
